Why uniQure (QURE) Is Up After Strong AMT-130 Data and $475 Million in New Funding

• uniQure N.V. recently announced positive topline results from its pivotal Phase I/II study of AMT-130 for Huntington’s disease, meeting its prespecified primary endpoint and demonstrating a statistically significant slowing of disease progression in high-dose patients over three years compared to an external control.
• This milestone was accompanied by a successful US$300 million follow-on equity offering and a new US$175 million term loan, positioning the company to advance regulatory submission efforts and prepare for potential commercialization of AMT-130.
• Now, we’ll assess how these promising clinical results and strengthened financing affect uniQure’s investment narrative and future prospects.

Outshine the giants: these 25 early-stage AI stocks could fund your retirement.

uniQure Investment Narrative Recap

To be a shareholder in uniQure, you need to believe the company can successfully bring AMT-130, its gene therapy for Huntington’s disease, through FDA approval and into commercial adoption. The recent positive Phase I/II results and funding boost directly support this pathway, strengthening the likelihood of hitting the short-term catalyst of a successful Biologics License Application, but do not eliminate regulatory and product-specific risks that could delay timelines or impact future revenue.

The US$300 million follow-on equity offering completed in September 2025 is particularly relevant, ensuring uniQure is well-capitalized to advance regulatory submissions and prepare for a potential product launch. This bolstered financial position also helps reduce near-term financing risk and supports ongoing work on AMT-130, which remains critical to the company's overall investment case.

However, investors should also be mindful that, despite recent progress, there are still important risks surrounding regulatory outcomes and ...

Read the full narrative on uniQure (it's free!)

uniQure's outlook anticipates $306.4 million in revenue and $32.3 million in earnings by 2028. This projection relies on a 147.5% annual revenue growth rate and a $249.9 million increase in earnings from the current -$217.6 million.

Uncover how uniQure's forecasts yield a $66.50 fair value, a 21% upside to its current price.

Exploring Other Perspectives

Six community members on Simply Wall St have projected uniQure’s fair value between US$13.55 and US$448.06 per share. With these varied outlooks in mind, consider that the next key test for the company remains the regulatory approval process, which could shape earnings prospects for years to come.

Explore 6 other fair value estimates on uniQure - why the stock might be worth over 8x more than the current price!

Build Your Own uniQure Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your uniQure research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.
• Our free uniQure research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate uniQure's overall financial health at a glance.

Searching For A Fresh Perspective?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• Uncover the next big thing with financially sound penny stocks that balance risk and reward.
• This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.
• We've found 19 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com